(firstQuint)Study of Eszopiclone Compared to Placebo on Daytime Function in Subjects With Insomnia Related to Rheumatoid Arthritis.

 A multicenter, randomized, double-blind, placebo controlled, parallel group study of eszopiclone 3 mg in subjects with insomnia related to rheumatoid arthritis.

 This study was previously posted by Sepracor Inc.

 In October 2009, Sepracor Inc.

 was acquired by Dainippon Sumitomo Pharma.

, and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.

.

 Study of Eszopiclone Compared to Placebo on Daytime Function in Subjects With Insomnia Related to Rheumatoid Arthritis@highlight

To demonstrate subjective sleep efficacy of eszopiclone 3 mg in subjects with insomnia related to rheumatoid arthritis (RA).

